Peimine
CAS No. : 23496-41-5
(Synonyms: Verticine; Dihydroisoimperialine)
| Size | Price | Stock |
|---|---|---|
| 5mg | $50 | In-stock |
| 10mg | $80 | In-stock |
| 25mg | $150 | In-stock |
| 50mg | $250 | In-stock |
| 100mg | $400 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-N0212 |
| M.Wt: | 431.65 |
| Formula: | C27H45NO3 |
| Purity: | >98 % |
| Solubility: | DMSO : 50 mg/mL (ultrasonic) |
Peimine (Verticine; Dihydroisoimperialine) is an orally active natural product. Peimine has anti-inflammatory, analgesic and cough relieving effects. Peimine can be used in cancer and inflammation related research[1][2][3][4][5][6][7].
In Vitro:Peimine (0-200 μM, 24 h) disrupts intracellular calcium homeostasis through the Ca2+/CaMKII/JNK pathway, inhibits the growth and movement of prostate cancer cells (DU-145, LNCap, and PC-3) and induces apoptosis, while having no significant effect on normal cells (RWPE-1) [3].
Peimine (0-25 mg/L, 1 h) has anti-inflammatory activity through regulating TNF-a, IL-6, IL-1b and IL-10 by suppressing the phosphorylation of MAPK and the activation of NF-kB in LPS-stimulated RAW 264.7 macrophages[6].
Peimine (10-300 μM, 0-10 ms) can block the Nav1.7 ion channel with an IC50 value of 47.2 μM, and can also inhibit the Kv1.3 ion channel with an IC50 value of 354.4 μM[7].
In Vivo:Peimine (32.5 μM/kg/day for 7days,i.g.) can effectively alleviate LPS-induced acute lung injury in mice, inhibit the expression levels of inflammatory factors TNF-α, IL-6, and IL-1 in mouse models, and has a synergistic effect when combined with Peiminine (HY-N0213) and Forsythoside. It can effectively improve its anti-inflammatory activity[4].
The drug level of Peimine (single oral 4.25 g/kg) in the blood and tissue of male rats is significantly higher than that of female rats (Reference 3)[5].
Pharmacokinetic Analysis in male and female SD Rats[5]
| Gender | Route | Dose (g/kg) | Cmax (ng/mL) | Tmax (h) | t1/2 (h) | MRT0-t (h) | MRT0-∞ (h) | AUC0-t (ng·h/mL) | AUC0-∞ (ng·h/mL) | CL/F (L/kg/h) | V/F (L/kg) |
| Female | p.o. | 4.25 | 43.7 | 1.5 | 4.2 | 7.8 | 7.9 | 214.2 | 214.3 | 128.9 | 781.3 |
| Male | p.o. | 4.25 | 57.6 | 2.9 | 6.2 | 7.2 | 7.4 | 662.4 | 665.3 | 41.5 | 374.1 |